PARSIPPANY — PurpleStride New Jersey 2017 was a powerful and inspiring day. Thanks to all of the amazing participants and teams, they have some fantastic news to share — they have met and surpassed our fundraising goal of $415,000! Together, they raised over $445,000. Ken Rosato, anchor of Channel 7 Eyewitness News in the Morning, emceed the event.
PurpleStride New Jersey 2017 was held in the Mack-Cali Campus on Sunday, November 12. Gold Sponsor was Ipsen Group; National Presenting Sponsor was Celgene and National Silver Sponsor was AbbVie.
To view results of the runners, click here. Out of the estimated 2,500 runners/walkers 16-year old Marco Cardone came in first place at 5:09.
PurpleStride walks are among the largest sources of funding for the Pancreatic Cancer Action Network. When you Wage Hope at PurpleStride, you join a vibrant community of survivors, impacted families, loved ones, researchers and advocates committed to rewriting the future of this deadly disease.
More patients die from pancreatic cancer than breast cancer, making pancreatic cancer the third leading cause of cancer-related death in the United States. Additionally, only 9% of patients live five years. To change the course of this disease, the New Jersey Affiliate of the Pancreatic Cancer Action Network is inviting the community to attend PurpleStride New Jersey: The Walk to End Pancreatic Cancer.
“We’re saving lives at PurpleStride New Jersey,” stated Sandi Field Affiliate Chair of the New Jersey Affiliate of the Pancreatic Cancer Action Network. “Every stride we make directly impacts the course of this disease. Our community needs this uplifting celebration of hope that unites families affected by the deadliest cancer. It’s time to take action against pancreatic cancer and make vigorous steps to double survival by 2020!”
The American Cancer Society reports an estimated 53,670 Americans will be diagnosed with pancreatic cancer and approximately 43,090 will die from the disease this year. The Pancreatic Cancer Action Network is working to double survival by 2020 by continuing to directly fund research, advocate for increased funding and resources from the national government, raise awareness through community outreach, and provide excellent patient services and support for novel initiatives like Clinical Trial Finder, Know Your Tumor personalized medicine service and the Patient Registry.
Learn more about how you can support your local New Jersey Affiliate and the Pancreatic Cancer Action Network by clicking here.
